Wednesday, May 1, 2019

The revolving door of Immunomedics is still spinning

It wasn't that long ago that CMO Rob Iannone was standing on the stage in San Diego accepting an award for best clinical candidate.

Now he is leaving Immunomedics shortly after the CEO departed and the recent rejection of their candidate sacituzumab govitecan. Phew, this has been an exhausting turn. And to be honest, I would be surprised if this was the end of the bad news.